AFINATOR
Everolimus (Afinator) is approved to treat:
- Breast cancer. Everolimus is used in combination with exemestane in post menopausal women with advanced hormone receptor positive (HR+) breast cancer that is also HER2 negative (HER2-) and has not gotten better with other chemotherapy.
- Pancreatic cancer. It is used in adults with progressive neuroendocrine tumorsthat cannot be removed by surgery, are locally advanced, or have metastasized(spread to other parts of the body).
- Renal cell carcinoma (a type of kidney cancer) that is advanced, in adults who have not gotten better with other chemotherapy.
- Subependymal giant cell astrocytoma in adults and children who have tuberous sclerosis and are not able to have surgery. Everolimus is available as tablets (Afinitor) or tablets for oral suspension (Afinitor Disperz). Only Afinitor Disperz is used in children.
AFINATOR
 | AFINATOR AVAILABLE AS: 5MG,tablets. (10 X 1 Tab Strip) 10MG,tablets (10 x 1 Tab Strip) MANUFACTURE BY: Novartis India. |
Recommended Dose:
Breast Cancer
Afinitor: Indicated in postmenopausal women with advanced hormone receptor-positive, HER2-negative breast cancer in combination with exemestane after failure of treatment with letrozole or anastrozole
10 mg PO qDay consistently with or without food (also see dosage modifications)
Advanced Pancreatic Neuroendocrine Tumors
Afinitor: Indicated for progressive neuroendocrine tumors (PNET) located in the pancreas that are not surgically resectable or are metastatic
10 mg PO qDay consistently with or without food (also see dosage modifications)
Renal Angiomyolipomas with TSC
Afinitor: Indicated for the treatment of noncancerous kidney tumors (renal angiomyolipomas) with tuberous sclerosis complex (TSC) in patients not requiring immediate surgery
10 mg PO qDay consistently with or without food (also see dosage modifications)
This medicine is to be taken strictly under Supervision of Medical Oncologist Only